{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T18:37:51Z","timestamp":1794335871044,"version":"4.9.0"},"reference-count":139,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T00:00:00Z","timestamp":1634860800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21AL143301-02"],"award-info":[{"award-number":["R21AL143301-02"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1TR001414-06"],"award-info":[{"award-number":["UL1TR001414-06"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Virology"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.coviro.2021.10.007","type":"journal-article","created":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T19:08:29Z","timestamp":1636139309000},"page":"179-189","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Therapeutic vaccination strategies against EBOV by rVSV-EBOV-GP: the role of innate immunity"],"prefix":"10.1016","volume":"51","author":[{"given":"Amanda N","family":"Pinski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3203-2405","authenticated-orcid":false,"given":"Ilhem","family":"Messaoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coviro.2021.10.007_bib0005","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(10)60667-8","article-title":"Ebola haemorrhagic fever","volume":"377","author":"Feldmann","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.coviro.2021.10.007_bib0010","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1189\/jlb.4RI0316-099RR","article-title":"Molecular mechanisms of Ebola pathogenesis","volume":"100","author":"Rivera","year":"2016","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.coviro.2021.10.007_bib0015","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1046\/j.1365-2249.2002.01800.x","article-title":"Inflammatory responses in Ebola virus-infected patients","volume":"128","author":"Baize","year":"2002","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.coviro.2021.10.007_bib0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0000837","article-title":"Human fatal Zaire Ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis","volume":"4","author":"Wauquier","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.coviro.2021.10.007_bib0025","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1016\/S0002-9440(10)63591-2","article-title":"Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection","volume":"163","author":"Geisbert","year":"2003","journal-title":"Am J Pathol"},{"key":"10.1016\/j.coviro.2021.10.007_sbref0030","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms8101473","article-title":"To B or Not to B: mechanisms of protection conferred by rVSV-EBOV-GP and the roles of innate and adaptive immunity","volume":"8","author":"Pinski","year":"2020","journal-title":"Microorganisms"},{"key":"10.1016\/j.coviro.2021.10.007_bib0035","series-title":"Ebola (Ebola Virus Disease)","author":"Outbreaks","year":"2021"},{"issue":"Suppl. 1","key":"10.1016\/j.coviro.2021.10.007_bib0040","doi-asserted-by":"crossref","first-page":"S259","DOI":"10.1086\/514302","article-title":"Ebola outbreak in Kikwit, Democratic Republic of the Congo: discovery and control measures","volume":"179","author":"Muyembe-Tamfum","year":"1999","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2021.10.007_bib0045","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.01803","article-title":"Advances in designing and developing vaccines, drugs, and therapies to counter Ebola virus","volume":"9","author":"Dhama","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.coviro.2021.10.007_bib0050","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1002\/jmv.25357","article-title":"Perspectives towards antiviral drug discovery against Ebola virus","volume":"91","author":"Mirza","year":"2019","journal-title":"J Med Virol"},{"key":"10.1016\/j.coviro.2021.10.007_bib0055","article-title":"Guinea 2021 EBOV genomes - ebolavirus\/guinea 2021 [Internet]","year":"2021","journal-title":"Virological"},{"key":"10.1016\/j.coviro.2021.10.007_bib0060","unstructured":"New Ebola Outbreak Likely Sparked by a Person Infected 5 Years Ago Science, AAAS [Internet]. [cited 2021 June 21]. Available from: https:\/\/www.sciencemag.org\/news\/2021\/03\/new-ebola-outbreak-likely-sparked-person-infected-5-years-ago."},{"key":"10.1016\/j.coviro.2021.10.007_bib0065","unstructured":"First FDA-approved vaccine for the prevention of Ebola virus disease, marking a critical milestone in public health preparedness and response [Internet]. FDA. FDA; 2020 [cited 2021 May 29]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/first-fda-approved-vaccine-prevention-ebola-virus-disease-marking-critical-milestone-public-health."},{"key":"10.1016\/j.coviro.2021.10.007_bib0070","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1126\/science.aad5224","article-title":"Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody","volume":"351","author":"Corti","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.coviro.2021.10.007_bib0075","series-title":"Research C for DE and FDA Approves Treatment for Ebola Virus","year":"2021"},{"key":"10.1016\/j.coviro.2021.10.007_sbref0080","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ebiom.2019.09.055","article-title":"Single low-dose VSV-EBOV vaccination protects cynomolgus macaques from lethal Ebola challenge","volume":"49","author":"Marzi","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.coviro.2021.10.007_bib0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0005547","article-title":"Mucosal immunization of cynomolgus macaques with the VSVDeltaG\/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses","volume":"4","author":"Qiu","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2021.10.007_bib0090","doi-asserted-by":"crossref","first-page":"6894","DOI":"10.1016\/j.vaccine.2008.09.082","article-title":"Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses","volume":"26","author":"Geisbert","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2021.10.007_bib0095","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1016\/j.celrep.2018.04.027","article-title":"Recently identified mutations in the Ebola virus-Makona genome do not alter pathogenicity in animal models","volume":"23","author":"Marzi","year":"2018","journal-title":"Cell Rep"},{"key":"10.1016\/j.coviro.2021.10.007_bib0100","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/nm1258","article-title":"Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses","volume":"11","author":"Jones","year":"2005","journal-title":"Nat Med"},{"key":"10.1016\/j.coviro.2021.10.007_bib0105","doi-asserted-by":"crossref","first-page":"S360","DOI":"10.1093\/infdis\/jiw218","article-title":"Efficacy of vesicular stomatitis virus\u2013Ebola virus postexposure treatment in rhesus macaques infected with Ebola virus Makona","volume":"214","author":"Marzi","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2021.10.007_bib0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.0030002","article-title":"Effective post-exposure treatment of Ebola infection","volume":"3","author":"Feldmann","year":"2007","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2021.10.007_bib0115","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1126\/science.aab3920","article-title":"VSV-EBOV rapidly protects macaques against infection with the 2014\/15 Ebola virus outbreak strain","volume":"349","author":"Marzi","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.coviro.2021.10.007_sbref0120","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-17446-4","article-title":"Prior vaccination with rVSV-ZEBOV does not interfere with but improves efficacy of postexposure antibody treatment","volume":"11","author":"Cross","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.coviro.2021.10.007_bib0125","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola \u00c7a Suffit!)","volume":"389","author":"Henao-Restrepo","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.coviro.2021.10.007_bib0130","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S0140-6736(15)61117-5","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial","volume":"386","author":"Henao-Restrepo","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.coviro.2021.10.007_bib0135","doi-asserted-by":"crossref","first-page":"98","DOI":"10.15585\/mmwr.su6503a14","article-title":"Implementing an Ebola vaccine study - Sierra Leone","volume":"65","author":"Widdowson","year":"2016","journal-title":"MMWR Suppl"},{"key":"10.1016\/j.coviro.2021.10.007_bib0140","doi-asserted-by":"crossref","first-page":"541","DOI":"10.3201\/eid2603.191018","article-title":"Pregnancy outcomes among women receiving rVSV\u0394-ZEBOV-GP Ebola vaccine during the Sierra Leone trial to introduce a vaccine against Ebola","volume":"26","author":"Legardy-Williams","year":"2020","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.coviro.2021.10.007_bib0145","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1093\/infdis\/jiy020","article-title":"The Sierra Leone trial to introduce a vaccine against Ebola: an evaluation of rVSV\u0394G-ZEBOV-GP vaccine tolerability and safety during the West Africa Ebola outbreak","volume":"217","author":"Samai","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2021.10.007_bib0150","doi-asserted-by":"crossref","DOI":"10.3390\/v11030274","article-title":"Ebola virus entry: from molecular characterization to drug discovery","volume":"11","author":"Salata","year":"2019","journal-title":"Viruses"},{"issue":"Suppl. 2","key":"10.1016\/j.coviro.2021.10.007_bib0155","doi-asserted-by":"crossref","first-page":"S404","DOI":"10.1086\/520591","article-title":"Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse model of Ebola virus hemorrhagic fever","volume":"196","author":"Jones","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2021.10.007_bib0160","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1128\/JVI.77.2.1069-1074.2003","article-title":"Identification of protective epitopes on Ebola virus glycoprotein at the single amino acid level by using recombinant vesicular stomatitis viruses","volume":"77","author":"Takada","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2021.10.007_bib0165","doi-asserted-by":"crossref","first-page":"14764","DOI":"10.1073\/pnas.94.26.14764","article-title":"A system for functional analysis of Ebola virus glycoprotein","volume":"94","author":"Takada","year":"1997","journal-title":"PNAS"},{"key":"10.1016\/j.coviro.2021.10.007_bib0170","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0092-8674(01)00482-2","article-title":"An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants","volume":"106","year":"2001","journal-title":"Cell"},{"key":"10.1016\/j.coviro.2021.10.007_bib0175","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.74.23.10903-10910.2000","article-title":"Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1","volume":"74","author":"Rose","year":"2000","journal-title":"J Virol"},{"issue":"Suppl. 1","key":"10.1016\/j.coviro.2021.10.007_bib0180","article-title":"Vesicular stomatitis virus-based vaccines for prophylaxis and treatment of filovirus infections","author":"Marzi","year":"2011","journal-title":"J Bioterror Biodef"},{"key":"10.1016\/j.coviro.2021.10.007_bib0185","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.virusres.2015.10.021","article-title":"Recent advances in the development of vaccines for Ebola virus disease","volume":"211","author":"Ohimain","year":"2016","journal-title":"Virus Res"},{"key":"10.1016\/j.coviro.2021.10.007_bib0190","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001567","article-title":"Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates","volume":"6","author":"Mire","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.coviro.2021.10.007_bib0195","doi-asserted-by":"crossref","first-page":"6597","DOI":"10.1016\/j.vaccine.2016.06.071","article-title":"Live virus vaccines based on a vesicular stomatitis virus (VSV) backbone: standardized template with key considerations for a risk\/benefit assessment","volume":"34","author":"Clarke","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2021.10.007_bib0200","doi-asserted-by":"crossref","DOI":"10.3390\/insects9040190","article-title":"Vesicular stomatitis virus transmission: a comparison of incriminated vectors","volume":"9","author":"Rozo-Lopez","year":"2018","journal-title":"Insects"},{"key":"10.1016\/j.coviro.2021.10.007_bib0205","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000225","article-title":"Vesicular stomatitis virus-based Ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates","volume":"4","author":"Geisbert","year":"2008","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2021.10.007_bib0210","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1056\/NEJMoa1614067","article-title":"Phase 2 placebo-controlled trial of two vaccines to prevent Ebola in Liberia","volume":"377","author":"Kennedy","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2021.10.007_bib0215","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/ni.2039","article-title":"Immunological mechanisms of vaccination","volume":"12","author":"Pulendran","year":"2011","journal-title":"Nat Immunol"},{"key":"10.1016\/j.coviro.2021.10.007_bib0220","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1586\/erv.10.152","article-title":"Progress in filovirus vaccine development: evaluating the potential for clinical use","volume":"10","author":"Falzarano","year":"2011","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.coviro.2021.10.007_sbref0225","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1080\/14760584.2020.1738225","article-title":"The Ebola virus glycoprotein and its immune responses across multiple vaccine platforms","volume":"19","author":"O\u2019Donnell","year":"2020","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.coviro.2021.10.007_bib0230","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1080\/21645515.2018.1473698","article-title":"The vesicular stomatitis virus-based Ebola virus vaccine: from concept to clinical trials","volume":"14","author":"Suder","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.coviro.2021.10.007_bib0235","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.3201\/eid2110.150259","article-title":"delayed disease progression in cynomolgus macaques infected with Ebola virus Makona strain","volume":"21","author":"Marzi","year":"2015","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.coviro.2021.10.007_bib0240","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002600","article-title":"Vesicular stomatitis virus-based vaccines protect nonhuman primates against Bundibugyo ebolavirus","volume":"7","author":"Mire","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.coviro.2021.10.007_bib0245","doi-asserted-by":"crossref","first-page":"7296","DOI":"10.1128\/JVI.00561-09","article-title":"Single-injection vaccine protects nonhuman primates against infection with Marburg Virus and three species of Ebola virus","volume":"83","author":"Geisbert","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2021.10.007_bib0250","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1073\/pnas.1209591110","article-title":"Antibodies are necessary for rVSV\/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates","volume":"110","author":"Marzi","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2021.10.007_bib0255","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1056\/NEJMoa1502924","article-title":"Phase 1 trials of rVSV Ebola vaccine in Africa and Europe","volume":"374","author":"Agnandji","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2021.10.007_bib0260","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002402","article-title":"Safety and immunogenicity of rVSV\u0394G-ZEBOV-GP Ebola vaccine in adults and children in Lambar\u00e9n\u00e9, Gabon: a phase I randomised trial","volume":"14","author":"Agnandji","year":"2017","journal-title":"PLoS Med"},{"key":"10.1016\/j.coviro.2021.10.007_bib0265","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S1473-3099(17)30313-4","article-title":"Safety and immunogenicity of the rVSV\u0394G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study","volume":"17","author":"Heppner","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.coviro.2021.10.007_bib0270","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1473-3099(18)30165-8","article-title":"Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study","volume":"18","author":"Huttner","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.coviro.2021.10.007_bib0275","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaj1701","article-title":"A dose-dependent plasma signature of the safety and immunogenicity of the rVSV-Ebola vaccine in Europe and Africa","volume":"9","author":"Huttner","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coviro.2021.10.007_sbref0280","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/S1473-3099(15)00154-1","article-title":"The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1\/2 trial","volume":"15","author":"Huttner","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.coviro.2021.10.007_bib0285","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1414216","article-title":"A recombinant vesicular stomatitis virus Ebola vaccine","volume":"376","author":"Regules","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2021.10.007_bib0290","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1038\/nm.4201","article-title":"Human antibody repertoire after VSV-Ebola vaccination identifies novel targets and virus-neutralizing IgM antibodies","volume":"22","author":"Khurana","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.coviro.2021.10.007_bib0295","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1038\/s41591-019-0602-4","article-title":"Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV","volume":"25","author":"Ehrhardt","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.coviro.2021.10.007_bib0300","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ebiom.2017.03.045","article-title":"Dose-dependent T-cell dynamics and cytokine cascade following rVSV-ZEBOV immunization","volume":"19","author":"Dahlke","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1016\/j.coviro.2021.10.007_bib0305","first-page":"1168","article-title":"Ebola virus disease in health care workers\u2014Sierra Leone, 2014","volume":"63","author":"Kilmarx","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.coviro.2021.10.007_bib0310","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1093\/infdis\/jix189","article-title":"Six-month safety data of recombinant vesicular stomatitis virus-Zaire Ebola virus envelope glycoprotein vaccine in a phase 3 double-blind, placebo-controlled randomized study in healthy adults","volume":"215","author":"Halperin","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2021.10.007_bib0315","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1093\/infdis\/jiz241","article-title":"Immunogenicity, lot consistency, and extended safety of rVSV\u0394G-ZEBOV-GP vaccine: a phase 3 randomized, double-blind, placebo-controlled study in healthy adults","volume":"220","author":"Halperin","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2021.10.007_bib0320","unstructured":"Preliminary Results on the Efficacy of rVSV-ZEBOV-GP Ebola Vaccine Using the Ring Vaccination Strategy in the Control of an Ebola Outbreak in the Democratic Republic of the Congo: an Example of Integration of Research into Epidemic Response. [cited 2021 June 7]. Available from: https:\/\/www.who.int\/publications\/m\/item\/preliminary-results-on-the-efficacy-of-rvsv-zebov-gp-ebola-vaccine-using-the-strategy-in-the-control-of-an-ebola-outbreak."},{"key":"10.1016\/j.coviro.2021.10.007_bib0325","article-title":"Longitudinal antibody and T cell responses in Ebola virus disease survivors and contacts: an observational cohort study","author":"Thom","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.coviro.2021.10.007_bib0330","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-21411-0","article-title":"Characterisation of the T-cell response to Ebola virus glycoprotein amongst survivors of the 2013\u201316 West Africa epidemic","volume":"12","author":"Tipton","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.coviro.2021.10.007_bib0335","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1093\/infdis\/jiaa268","article-title":"Ebola-specific CD8+ and CD4+ T-cell responses in Sierra Leonean Ebola virus survivors with or without post-Ebola sequelae","volume":"222","author":"LaVergne","year":"2020","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2021.10.007_bib0340","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1093\/infdis\/jiz364","article-title":"Survivors of Ebola virus disease develop polyfunctional antibody responses","volume":"221","author":"Gunn","year":"2020","journal-title":"J Infect Dis"},{"issue":"Suppl. 1","key":"10.1016\/j.coviro.2021.10.007_bib0345","doi-asserted-by":"crossref","first-page":"S177","DOI":"10.1086\/514321","article-title":"Clinical virology of Ebola hemorrhagic fever (EHF): virus, virus antigen, and IgG and IgM antibody findings among EHF patients in Kikwit, Democratic Republic of the Congo, 1995","volume":"179","author":"Ksiazek","year":"1999","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2021.10.007_bib0350","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/7422","article-title":"Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients","volume":"5","author":"Baize","year":"1999","journal-title":"Nat Med"},{"key":"10.1016\/j.coviro.2021.10.007_bib0355","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.3201\/eid1507.090402","article-title":"Immunoglobulin G in Ebola outbreak survivors, Gabon","volume":"15","author":"Wauquier","year":"2009","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.coviro.2021.10.007_bib0360","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature13777","article-title":"Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp","volume":"514","author":"Qiu","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2021.10.007_bib0365","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003876","article-title":"Successful treatment of Ebola virus-infected cynomolgus macaques with monoclonal antibodies","volume":"4","author":"Qiu","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coviro.2021.10.007_bib0370","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJMoa1604330","article-title":"A randomized, controlled trial of ZMapp for Ebola virus infection","volume":"375","author":"PREVAIL II Writing Group","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2021.10.007_bib0375","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","article-title":"A randomized, controlled trial of Ebola virus disease therapeutics","volume":"381","author":"Mulangu","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2021.10.007_bib0380","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.smim.2018.07.003","article-title":"Correlates of vaccine-induced protective immunity against Ebola virus disease","volume":"39","author":"Medaglini","year":"2018","journal-title":"Semin Immunol"},{"key":"10.1016\/j.coviro.2021.10.007_bib0385","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nrd.2017.251","article-title":"Post-exposure treatments for Ebola and Marburg virus infections","volume":"17","author":"Cross","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.coviro.2021.10.007_bib0390","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad9875","article-title":"Two-mAb cocktail protects macaques against the Makona variant of Ebola virus","volume":"8","author":"Qiu","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coviro.2021.10.007_bib0395","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1001\/jama.2015.1995","article-title":"Emergency postexposure vaccination with vesicular stomatitis virus-vectored Ebola vaccine after needlestick","volume":"313","author":"Lai","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.coviro.2021.10.007_bib0400","doi-asserted-by":"crossref","first-page":"S785","DOI":"10.1093\/infdis\/jir298","article-title":"Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany","volume":"204","author":"G\u00fcnther","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2021.10.007_bib0405","doi-asserted-by":"crossref","first-page":"5664","DOI":"10.1128\/JVI.00456-08","article-title":"Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates","volume":"82","author":"Geisbert","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2021.10.007_bib0410","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S0140-6736(06)68546-2","article-title":"Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment","volume":"367","author":"Daddario-DiCaprio","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.coviro.2021.10.007_bib0415","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-20228-7","article-title":"A single dose of recombinant VSV-\u0394G-spike vaccine provides protection against SARS-CoV-2 challenge","volume":"11","author":"Yahalom-Ronen","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.coviro.2021.10.007_bib0420","doi-asserted-by":"crossref","first-page":"12781","DOI":"10.1128\/JVI.00794-11","article-title":"Vesicular stomatitis virus-based vaccine protects hamsters against lethal challenge with Andes virus","volume":"85","author":"Brown","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2021.10.007_sbref0425","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41541-019-0155-z","article-title":"A single dose of a vesicular stomatitis virus-based influenza vaccine confers rapid protection against H5 viruses from different clades","volume":"5","author":"Furuyama","year":"2020","journal-title":"npj Vaccines"},{"key":"10.1016\/j.coviro.2021.10.007_sbref0430","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.03071","article-title":"Protection against Marburg virus using a recombinant VSV-vaccine depends on T and B cell activation","volume":"9","author":"Marzi","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.coviro.2021.10.007_bib0435","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0094355","article-title":"Durability of a vesicular stomatitis virus-based Marburg virus vaccine in nonhuman primates","volume":"9","author":"Mire","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2021.10.007_bib0440","doi-asserted-by":"crossref","first-page":"11043","DOI":"10.1038\/s41598-018-29401-x","article-title":"A VSV-based Zika virus vaccine protects mice from lethal challenge","volume":"8","author":"Emanuel","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.coviro.2021.10.007_bib0445","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.1128\/JVI.73.5.3723-3732.1999","article-title":"Attenuated vesicular stomatitis viruses as vaccine vectors","volume":"73","author":"Roberts","year":"1999","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2021.10.007_bib0450","doi-asserted-by":"crossref","first-page":"13231","DOI":"10.1128\/JVI.79.21.13231-13238.2005","article-title":"A single-cycle vaccine vector based on vesicular stomatitis virus can induce immune responses comparable to those generated by a replication-competent vector","volume":"79","author":"Publicover","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2021.10.007_bib0455","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1099\/jgv.0.001085","article-title":"Immunogenicity of propagation-restricted vesicular stomatitis virus encoding Ebola virus glycoprotein in guinea pigs","volume":"99","author":"Locher","year":"2018","journal-title":"J Gen Virol"},{"key":"10.1016\/j.coviro.2021.10.007_bib0460","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1128\/JVI.05991-11","article-title":"The immune response to a vesicular stomatitis virus vaccine vector is independent of particulate antigen secretion and protein turnover rate","volume":"86","author":"Cobleigh","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2021.10.007_sbref0465","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1093\/infdis\/jiy565","article-title":"Detectable vesicular stomatitis virus (VSV)\u2013specific humoral and cellular immune responses following VSV\u2013Ebola virus vaccination in humans","volume":"219","author":"Poetsch","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2021.10.007_bib0470","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1073\/pnas.0811014106","article-title":"Tetherin-mediated restriction of filovirus budding is antagonized by the Ebola glycoprotein","volume":"106","author":"Kaletsky","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2021.10.007_bib0475","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1159\/000485143","article-title":"Immune consequences of in vitro infection of human peripheral blood leukocytes with vesicular stomatitis virus","volume":"10","author":"Tomczyk","year":"2018","journal-title":"J Innate Immun"},{"key":"10.1016\/j.coviro.2021.10.007_bib0480","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.virol.2009.06.032","article-title":"RIG-I activation inhibits ebolavirus replication","volume":"392","author":"Spiropoulou","year":"2009","journal-title":"Virology"},{"key":"10.1016\/j.coviro.2021.10.007_bib0485","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1128\/JVI.01875-08","article-title":"Ebola virus protein VP35 impairs the function of interferon regulatory factor-activating kinases IKK\u03b5 and TBK-1","volume":"83","author":"Prins","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2021.10.007_bib0490","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/s41598-017-01032-8","article-title":"Transcriptomic analysis reveals a previously unknown role for CD8+ T-cells in rVSV-EBOV mediated protection","volume":"7","author":"Menicucci","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.coviro.2021.10.007_sbref0495","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00597-19","article-title":"Antiviral Innate responses induced by VSV-EBOV vaccination contribute to rapid protection","volume":"10","author":"Menicucci","year":"2019","journal-title":"mBio"},{"key":"10.1016\/j.coviro.2021.10.007_bib0500","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1016\/j.celrep.2017.08.023","article-title":"Systems vaccinology identifies an early innate immune signature as a correlate of antibody responses to the Ebola vaccine rVSV-ZEBOV","volume":"20","author":"Rechtien","year":"2017","journal-title":"Cell Rep"},{"key":"10.1016\/j.coviro.2021.10.007_sbref0505","article-title":"Human transcriptomic response to the VSV-vectored Ebola vaccine","volume":"9","author":"Santoro","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.coviro.2021.10.007_bib0510","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1038\/ni1138","article-title":"Induced recruitment of NK cells to lymph nodes provides IFN-\u03b3 for TH1 priming","volume":"5","author":"Mart\u00edn-Fontecha","year":"2004","journal-title":"Nat Immunol"},{"key":"10.1016\/j.coviro.2021.10.007_bib0515","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.immuni.2012.03.026","article-title":"NK cell-derived interferon-\u03b3 orchestrates cellular dynamics and the differentiation of monocytes into dendritic cells at the site of infection","volume":"36","author":"Goldszmid","year":"2012","journal-title":"Immunity"},{"key":"10.1016\/j.coviro.2021.10.007_bib0520","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1172\/JCI116479","article-title":"Evidence for antiviral effect of nitric oxide. Inhibition of herpes simplex virus type 1 replication","volume":"91","author":"Croen","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coviro.2021.10.007_bib0525","doi-asserted-by":"crossref","first-page":"E10915","DOI":"10.1073\/pnas.1811615115","article-title":"IL-15 enhanced antibody-dependent cellular cytotoxicity mediated by NK cells and macrophages","volume":"115","author":"Zhang","year":"2018","journal-title":"PNAS"},{"key":"10.1016\/j.coviro.2021.10.007_bib0530","doi-asserted-by":"crossref","first-page":"4279","DOI":"10.4049\/jimmunol.169.8.4279","article-title":"Coordinated and distinct roles for IFN-alpha beta, IL-12, and IL-15 regulation of NK cell responses to viral infection","volume":"169","author":"Nguyen","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.coviro.2021.10.007_bib0535","doi-asserted-by":"crossref","first-page":"930","DOI":"10.3389\/fimmu.2017.00930","article-title":"Developmental and functional control of natural killer cells by cytokines","volume":"8","author":"Wu","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.coviro.2021.10.007_bib0540","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1146\/annurev.immunol.17.1.189","article-title":"Natural killer cells in antiviral defense: function and regulation by innate cytokines","volume":"17","author":"Biron","year":"1999","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.coviro.2021.10.007_bib0545","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005645","article-title":"Different features of V\u03b42 T and NK cells in fatal and non-fatal human Ebola infections","volume":"11","author":"Cimini","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.coviro.2021.10.007_bib0550","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s00251-010-0480-x","article-title":"Association of KIR2DS1 and KIR2DS3 with fatal outcome in Ebola virus infection","volume":"62","author":"Wauquier","year":"2010","journal-title":"Immunogenetics"},{"key":"10.1016\/j.coviro.2021.10.007_bib0555","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1084\/jem.20032141","article-title":"Role of natural killer cells in innate protection against lethal Ebola virus infection","volume":"200","author":"Warfield","year":"2004","journal-title":"J Exp Med"},{"key":"10.1016\/j.coviro.2021.10.007_bib0560","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1111\/j.1462-5822.2006.00844.x","article-title":"NKp30-dependent cytolysis of filovirus-infected human dendritic cells","volume":"9","author":"Fuller","year":"2007","journal-title":"Cell Microbiol"},{"key":"10.1016\/j.coviro.2021.10.007_bib0565","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1089\/vim.2014.0069","article-title":"VSV\u0394G\/EBOV GP-induced innate protection enhances natural killer cell activity to increase survival in a lethal mouse adapted Ebola virus infection","volume":"28","author":"Williams","year":"2015","journal-title":"Viral Immunol"},{"key":"10.1016\/j.coviro.2021.10.007_bib0570","first-page":"121","article-title":"CXCL10\/IP-10 in infectious diseases pathogenesis and potential therapeutic implications","volume":"22","author":"Liu","year":"2011","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.coviro.2021.10.007_sbref0575","first-page":"1","article-title":"Rapid dose-dependent natural killer (NK) cell modulation and cytokine responses following human rVSV-ZEBOV Ebolavirus vaccination","volume":"5","author":"Pejoski","year":"2020","journal-title":"npj Vaccines"},{"key":"10.1016\/j.coviro.2021.10.007_bib0580","doi-asserted-by":"crossref","first-page":"10442","DOI":"10.1128\/JVI.79.16.10442-10450.2005","article-title":"Effects of Ebola virus glycoproteins on endothelial cell activation and barrier function","volume":"79","author":"Wahl-Jensen","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2021.10.007_bib0585","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.virol.2003.12.014","article-title":"Ebola virus glycoprotein-mediated anoikis of primary human cardiac microvascular endothelial cells","volume":"321","author":"Ray","year":"2004","journal-title":"Virology"},{"key":"10.1016\/j.coviro.2021.10.007_bib0590","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1128\/jvi.76.5.2518-2528.2002","article-title":"Ebola virus glycoproteins induce global surface protein down-modulation and loss of cell adherence","volume":"76","author":"Simmons","year":"2002","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2021.10.007_bib0595","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1099\/vir.0.81361-0","article-title":"Ebola virus glycoprotein GP is not cytotoxic when expressed constitutively at a moderate level","volume":"87","author":"Alazard-Dany","year":"2006","journal-title":"J Gen Virol"},{"key":"10.1016\/j.coviro.2021.10.007_bib0600","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00179-17","article-title":"Ebolaviruses associated with differential pathogenicity induce distinct host responses in human macrophages","volume":"91","author":"Olejnik","year":"2017","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2021.10.007_bib0605","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1089\/jir.2013.0035","article-title":"Ebola virus-like particles stimulate type I interferons and proinflammatory cytokine expression through the toll-like receptor and interferon signaling pathways","volume":"34","author":"Ayithan","year":"2014","journal-title":"J Interferon Cytokine Res"},{"key":"10.1016\/j.coviro.2021.10.007_bib0610","doi-asserted-by":"crossref","first-page":"S327","DOI":"10.1093\/infdis\/jiy406","article-title":"Ebola virus shed glycoprotein triggers differentiation, infection, and death of monocytes through toll-like receptor 4 activation","volume":"218","author":"Iampietro","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2021.10.007_bib0615","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004509","article-title":"Shed GP of Ebola virus triggers immune activation and increased vascular permeability","volume":"10","author":"Escudero-P\u00e9rez","year":"2014","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2021.10.007_bib0620","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1128\/JVI.01810-14","article-title":"Less is more: Ebola virus surface glycoprotein expression levels regulate virus production and infectivity","volume":"89","author":"Mohan","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2021.10.007_bib0625","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003065","article-title":"Antigenic subversion: a novel mechanism of host immune evasion by Ebola virus","volume":"8","author":"Mohan","year":"2012","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2021.10.007_bib0630","doi-asserted-by":"crossref","first-page":"16128","DOI":"10.1038\/nmicrobiol.2016.128","article-title":"Structures of Ebola virus GP and sGP in complex with therapeutic antibodies","volume":"1","author":"Pallesen","year":"2016","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.coviro.2021.10.007_bib0635","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.cellimm.2017.11.009","article-title":"Ebola virus secreted glycoprotein decreases the anti-viral immunity of macrophages in early inflammatory responses","volume":"324","author":"Bradley","year":"2018","journal-title":"Cell Immunol"},{"key":"10.1016\/j.coviro.2021.10.007_sbref0640","doi-asserted-by":"crossref","DOI":"10.3390\/v11110999","article-title":"The roles of Ebola virus soluble glycoprotein in replication, pathogenesis, and countermeasure development","volume":"11","author":"Zhu","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.coviro.2021.10.007_bib0645","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1128\/JVI.79.4.2413-2419.2005","article-title":"Role of Ebola virus secreted glycoproteins and virus-like particles in activation of human macrophages","volume":"79","author":"Wahl-Jensen","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2021.10.007_bib0650","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1128\/JVI.01462-09","article-title":"Interaction between Ebola virus glycoprotein and host toll-like receptor 4 leads to induction of proinflammatory cytokines and SOCS1","volume":"84","author":"Okumura","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2021.10.007_bib0655","doi-asserted-by":"crossref","first-page":"15889","DOI":"10.1073\/pnas.2237038100","article-title":"Ebola virus-like particles protect from lethal Ebola virus infection","volume":"100","author":"Warfield","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2021.10.007_bib0660","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.virol.2007.03.020","article-title":"Ebola virus-like particle-induced activation of NF-kappaB and Erk signaling in human dendritic cells requires the glycoprotein mucin domain","volume":"364","author":"Martinez","year":"2007","journal-title":"Virology"},{"key":"10.1016\/j.coviro.2021.10.007_bib0665","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0007819","article-title":"IL-4\/IL-13 polarization of macrophages enhances Ebola virus glycoprotein-dependent infection","volume":"13","author":"Rogers","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.coviro.2021.10.007_bib0670","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006397","article-title":"Ebola virus glycoprotein directly triggers T lymphocyte death despite of the lack of infection","volume":"13","author":"Iampietro","year":"2017","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2021.10.007_bib0675","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008068","article-title":"Ebola virus-mediated T-lymphocyte depletion is the result of an abortive infection","volume":"15","author":"Younan","year":"2019","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2021.10.007_bib0680","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/labinvest.3780021","article-title":"Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses","volume":"80","author":"Geisbert","year":"2000","journal-title":"Lab Invest"},{"key":"10.1016\/j.coviro.2021.10.007_bib0685","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00845-17","article-title":"Ebola virus binding to Tim-1 on T lymphocytes induces a cytokine storm","volume":"8","author":"Younan","year":"2017","journal-title":"mBio"},{"key":"10.1016\/j.coviro.2021.10.007_bib0690","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.3389\/fmicb.2017.01571","article-title":"Ebola virus glycoprotein induces an innate immune response in vivo via TLR4","volume":"8","author":"Lai","year":"2017","journal-title":"Front Microbiol"},{"key":"10.1016\/j.coviro.2021.10.007_sbref0695","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1093\/infdis\/jiz518","article-title":"Randomized, blinded, dose-ranging trial of an Ebola virus glycoprotein nanoparticle vaccine with matrix-M adjuvant in healthy adults","volume":"222","author":"Fries","year":"2020","journal-title":"J Infect Dis"}],"container-title":["Current Opinion in Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625721001292?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625721001292?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T08:03:38Z","timestamp":1778832218000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879625721001292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":139,"alternative-id":["S1879625721001292"],"URL":"https:\/\/doi.org\/10.1016\/j.coviro.2021.10.007","relation":{},"ISSN":["1879-6257"],"issn-type":[{"value":"1879-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic vaccination strategies against EBOV by rVSV-EBOV-GP: the role of innate immunity","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coviro.2021.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}